Detalles de la búsqueda
1.
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
Br J Cancer
; 118(5): 629-633, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29241223
2.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Breast Cancer Res Treat
; 168(1): 69-77, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29128898
3.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Mod Pathol
; 29(10): 1155-64, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27363491
4.
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
J Natl Cancer Inst
; 109(4)2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28122895
5.
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
JAMA Oncol
; 3(3): 335-341, 2017 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27812689
6.
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
JAMA Oncol
; 2(9): 1162-9, 2016 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27270348
7.
Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors-Reply.
JAMA Oncol
; 4(1): 132-133, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28973296
8.
Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.
J Clin Oncol
; 33(31): 3671-2, 2015 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26282639
Resultados
1 -
8
de 8
1
Próxima >
>>